Skip to main content
All lobbying filings

PERSONALIZED MEDICINE COALITION

PERSONALIZED MEDICINE COALITION filed a Q1 report for PERSONALIZED MEDICINE COALITION on April 20, 2026.

Lobbying for PERSONALIZED MEDICINE COALITION · Health care

All filings by PERSONALIZED MEDICINE COALITION · Everything PERSONALIZED MEDICINE COALITION has reported

 Filing · LD-2 quarterly report Q1 report
Reporting period
1st Quarter 2026
Jan 1 - Mar 31 · Posted Apr 20, 2026
Expenses
$40,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
District of Columbia

Official filing document

 Lobbyists on this filing 1
  • CYNTHIA BENS
    Previously held: Staff, Representative Paul E. Kanjorski

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 4

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 2
Budget/Appropriations

FY 2027 Food and Drug Administration Budget Priorities for CDER, CBER and CDRH FY 2027 National Institutes of Health Budget Priorities Reauthorization of the Prescription Drug User Fee Act; PFUFA VIII Reauthorization of the Medical Device User Fee Act; MDUFA VI

Health Issues

Congressional Personalized Medicine Caucus Genetic Testing and Genomic Sequencing for Rare Diseases S. 832/H.R. 1492 the Ensuring Pathways to Innovative Cures Act H.R. 946 Optimizing Research Progress Hope and New Cures Act H.R. 1672 Maintaining Investments in New Innovation Act S.2761/H.R.5269 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act Implementation of the Inflation Reduction Act of 2022 Medicare Drug Price Negotiation Provisions Implementation of Rural Health Transformation Program Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model [CMS-5546-P] Global Benchmark for Efficient Drug Pricing (GLOBE) Model [CMS-5545-P] Reclassification of Nucleic Acid-Based Test Systems for Use with a Corresponding Approved Oncology Therapeutic Product; Proposed Amendment; Proposed Order; Request for Comments [Docket No. FDA-2025-N-4622] Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community

 Bills named in this filing 6
  • S. 832
    EPIC Act of 2025
  • H.R. 1492
    To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
  • H.R. 946
    ORPHAN Cures Act
  • H.R. 1672
    Maintaining Investments in New Innovation Act
  • S. 2761
    RESULTS Act
  • H.R. 5269
    RESULTS Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem